(Cold Spring Harbor Laboratory) A team of scientists at Cold Spring Harbor Laboratory has published research identifying an enzyme called Brk as a target for future drugs to fight a virulent subset of cancers overexpressing a protein called ErbB2 -- also often called HER2 -- which drives tumor cells to proliferate unchecked. Brk, they report, helps these tumors become virulent and is also implicated in the process through which the tumors develop drug resistance to "targeted" therapies Herceptin and Lapatinib.
Source:http://www.eurekalert.org
Discuss Bury
Source:http://www.eurekalert.org
Discuss Bury
Medinews is an online community dedicated for promoting and discussing latest medical news, research articles and blogs. You can also find regular updates on health news for discussion by health professionals.
Comments